Company Profile

Abeome Corporation
Profile last edited on: 2/20/20      CAGE: 47GD0      UEI: GSGQJ6BDSHJ3

Business Identifier: Novel, proprietary platform technology to improve selection of high-affinity monoclonal antibodies
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

111 Riverbend Road Suite 145
Athens, GA 30605
   (706) 542-7889
Location: Single
Congr. District: 10
County: Clarke

Public Profile

Abeome is a biotechnology company leveraging a novel, proprietary platform technology to significantly improve the selection of high-affinity monoclonal antibodies. Over the past decade, monoclonal antibodies have emerged as one of the most important therapeutic elements in pharmaceuticals today, as well as the key to new diagnostic products and a critical research tool throughout the life sciences sector. Monoclonal antibodies are typically created using hybridoma technology; that is, fusing antibody-producing B cells with non-antibody-producing cancer cells (usually a myeloma). These hybridomas are then "immortal" and produce a range of antibodies of interest to medical researchers. The core challenge to researchers is to identify and isolate hybridomas that only produce antibodies for a particular antigen. Abeome's technology is focused on breaking down the two major bottlenecks of screening of hybridomas: quality and speed. Abeome's DiSH (Direct Selection of Hybridomas) technology offers a dramatically improved process for rapidly selecting desired hybridomas that are genetically stable and produce antibodies with optimal binding characteristics. Through genetic engineering techniques, Abeome is able to get desired hybridomas by using fluorescent labeled antigens. After labeling, the hybridomas can be efficiently screened and cloned using high speed fluorescence-activated cell sorting (FACS) instrumentation.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2017 2 NIH $1,724,538
Project Title: Novel Therapeutic Approach to Hypercholesterolemia Using Next-Generation DNA Sequencing
2013 1 NIH $275,916
Project Title: Semi-Targeted Immuno-Therapeutic Approach For Treatment Of Obesity
2010 1 NIH $133,995
Project Title: Development Of A Transgenic Mouse Line Engineered To Permit Selection And Cloning
2004 1 NIH $100,000
Project Title: Novel Markers on Human Embryonic Stem Cells
2004 1 NIH $100,000
Project Title: Novel C elegans Reagents

Key People / Management

  Richard Shimkets -- President & CEO

  Kirby Alton -- Executive Chairman

  Richard Meagher -- Chief Science Officer

  Paul W Price

  Michael Wanner -- Former Chief Executive Officer

Company News

There are no news available.